CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate.

Autor: Mungra N; Institute of Infectious Disease and Molecular Medicine, Medical Biotechnology and Immunotherapy Research Unit, University of Cape Town, Cape Town, 7700, South Africa.; Centre for Immunity and Immunotherapies, Seattle Children's Research Institute, Washington, 98101, USA., Biteghe FAN; Department of Radiation Oncology and Biomedical Sciences, Cedars-Sinai Medical, Los Angeles, USA., Malindi Z; Institute of Infectious Disease and Molecular Medicine, Medical Biotechnology and Immunotherapy Research Unit, University of Cape Town, Cape Town, 7700, South Africa.; Faculty of Health Sciences, Laser Research Centre, University of Johannesburg, Doornfontein, Johannesburg, 2028, South Africa., Huysamen AM; Department of Chemistry, PD Hahn Building, University of Cape Town, Cape Town, 7700, South Africa., Karaan M; Institute of Infectious Disease and Molecular Medicine, Medical Biotechnology and Immunotherapy Research Unit, University of Cape Town, Cape Town, 7700, South Africa., Hardcastle NS; Institute of Infectious Disease and Molecular Medicine, Medical Biotechnology and Immunotherapy Research Unit, University of Cape Town, Cape Town, 7700, South Africa., Bunjun R; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, 7700, South Africa.; Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, 7700, South Africa., Chetty S; Faculty of Health Sciences, School of Clinical Medicine, University of Witwatersrand, Braamfontein, Johannesburg, 2000, South Africa., Naran K; Institute of Infectious Disease and Molecular Medicine, Medical Biotechnology and Immunotherapy Research Unit, University of Cape Town, Cape Town, 7700, South Africa., Lang D; Division of Physiological Sciences, Department of Human Biology, University of Cape Town, Cape Town, 7700, South Africa., Richter W; TUBE Pharmaceuticals, 1110, Vienna, Austria., Hunter R; Department of Chemistry, PD Hahn Building, University of Cape Town, Cape Town, 7700, South Africa., Barth S; Institute of Infectious Disease and Molecular Medicine, Medical Biotechnology and Immunotherapy Research Unit, University of Cape Town, Cape Town, 7700, South Africa. stefan.barth@uct.ac.za.; Faculty of Health Sciences, Department of Integrative Biomedical Sciences, South African Research Chair in Cancer Biotechnology, University of Cape Town, Cape Town, 7700, South Africa. stefan.barth@uct.ac.za.

Publikováno v: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Oct; Vol. 149 (13), pp. 12203-12225. Date of Electronic Publication: 2023 Jul 11.

A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG ⁺ hybridomas in comparison to its recombinant allergen-drug conjugate.

Autor: Daramola AK; South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Medical Biotechnology & Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Akinrinmade OA; South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Medical Biotechnology & Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA., Fajemisin EA; South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Medical Biotechnology & Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Naran K; South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Medical Biotechnology & Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Mthembu N; Division of Immunology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Hadebe S; Division of Immunology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Brombacher F; Division of Immunology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; International Centre for Genetic Engineering and Biotechnology (ICGEB) and Institute of Infectious Diseases and Molecular Medicine (IDM), Division of Immunology, Faculty of Health Sciences, University of Cape Town, South Africa.; Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, South Africa., Huysamen AM; Department of Chemistry, Faculty of Sciences, University of Cape Town, Cape Town, South Africa., Fadeyi OE; Department of Chemistry, Faculty of Sciences, University of Cape Town, Cape Town, South Africa., Hunter R; Department of Chemistry, Faculty of Sciences, University of Cape Town, Cape Town, South Africa., Barth S; South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.; Medical Biotechnology & Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Publikováno v: Immunotherapy advances [Immunother Adv] 2022 Dec 06; Vol. 3 (1), pp. ltac023. Date of Electronic Publication: 2022 Dec 06 (Print Publication: 2023).